Empagliflozin Leads to a Rapid and Sustained Improvement of Left Ventricular Filling Pressure in Patients With Type 2 Diabetes: a Randomized Controlled Study

Preprint

4 August 2020

preprint
Published by Research Square Platform LLC

https://doi.org/10.21203/rs.3.rs-45927/v1

Abstract

BackgroundIn the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial) treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin significantly reduced heart failure hospitalization (HHF) in patients with type 2 diabetes mellitus (T2D) and esta...

Keywords

TREATMENT
FUNCTION
DIABETES
HEMODYNAMIC
EMPAGLIFLOZIN
HRS
VENTRICULAR FILLING PRESSURE

Other Versions

Published version: Version Cardiovascular Diabetology, 20, preprints